Selection and Treatment of Subjects with a Circulating Myeloid Cell Inflammatory Phenotype
By measuring CD14+CD16+ myeloid cells to identify an inflammatory phenotype, the method effectively targets and treats neuroinflammatory and neurodegenerative diseases using TQS-168, addressing the challenge of assessing Ppargc1α expression in patients.
Patent Information
- Application Number
- JP2024526580
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-02
- Filing Date
- 2022-11-01
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for clinically accessible markers to assess and monitor the effectiveness of activators of Ppargc1α (PGC-1α) expression in patients with neurodegenerative diseases like ALS, as bone marrow-mediated inflammation in the CNS is difficult to assess in vivo.
The method involves measuring the baseline concentration of CD14+CD16+ myeloid cells in a biological sample from a subject and determining if it exceeds a predetermined threshold to identify an inflammatory phenotype, using compounds like TQS-168 to suppress these cells, which are associated with neuroinflammatory and neurodegenerative diseases.
This approach allows for the identification and treatment of patients with neuroinflammatory and neurodegenerative diseases by suppressing CD14+CD16+ myeloid cells, potentially slowing down the progression of these conditions.
Smart Images

Figure 2024542097000001_ABST
Abstract
Description
[Technical field]
[0001] 1. CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 274,931, filed November 2, 2021, which is incorporated herein by reference in its entirety. [Background technology]
[0002] 2. Background of the Invention TQS-168 (2-(4-tert-butylphenyl)-1H-benzimidazole), formerly known as ZLN-005, is known to be an activator of Ppargc1α (PGC-1α) expression (Zhang et al., Diabetes 62:1297-1307 (2013)), but its immediate target, its direct molecular binding partner, is unknown. TQS-168 has previously been shown to suppress bone marrow-mediated inflammation in the central nervous system and reduce disease severity in mouse models of neurodegenerative diseases in which neuroinflammation contributes to the underlying pathophysiology, including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS) (U.S. Pat. Nos. 10,272,070; 10,583,125; and 10,653,669, the disclosures of which are incorporated herein by reference in their entireties). TQS-168 has also been shown to suppress metabolic dysfunction in microglial cells in aged mice, inhibit inflammatory cytokine production in microglial cells in aged mice, suppress systemic inflammation in aged mice, and alleviate behavioral dysfunction in aged mice (U.S. Pat. No. 10,653,669, the disclosure of which is incorporated herein by reference in its entirety). CNS bone marrow-mediated inflammation, especially the inflammatory state of microglial cells in the central nervous system, cannot be easily evaluated in vivo.Therefore, there is a need for a clinically accessible marker that can be used to identify and select patients for treatment with TQS-168 and other 2-aryl-benzimidazole compounds, and can be used to monitor and titrate the treatment of such patients.There is a particular need for a method to evaluate and monitor the effectiveness of activators of Ppargc1α (PGC-1α) expression in human ALS patients. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] U.S. Patent No. 10,272,070 [Patent Document 2] U.S. Pat. No. 10,583,125 [Patent Document 3] U.S. Pat. No. 10,653,669 Summary of the Invention [Means for solving the problem]
[0004] 3. Summary of the Invention As detailed in the experimental examples of the present disclosure, the inventors have found that the compound of formula I suppresses or induces / promotes the suppression of the proinflammatory phenotype of circulating myeloid cells from ALS patients in vitro.As shown herein, individuals with ALS exhibit higher expression of proinflammatory CD14+CD16+ circulating myeloid cells when compared with healthy populations.Presentation of compound I to biological samples from ALS patients showed the suppression and reduction of CD14+CD16+ circulating myeloid cells in vitro.Suppression of proinflammatory CD14+CD16+ circulating myeloid cells will be effective in treating, preventing the onset of, or slowing down the progression of neuroinflammatory and neurodegenerative diseases that express the proinflammatory phenotype of circulating myeloid cells.
[0005] Thus, in a first aspect, a compound of formula I [ka] or a salt, hydrate, deuterated analog, or fluorinated analog thereof [In the formula, Ar is [ka] and; W 1 is NR 1 , O, and S, or W 9 If N, then W 1 In addition, CR 50 It may be; W 2 CR 2 or N; W 3 CR 3 or N; W 4 CR 4 or N; W 5 CR 5 or N; W 6 CR6 or N; W 7 CR 7 or N; W 8 CR 8 or N; W 9 is C or W 1 CR 50 If W 9 may be N; R 1 is H, (C1-C3) alkyl, -CH2OC(=O)R 30 , -CH2OP(=O)OR 40 OR 41 , -C(=O)OR 42 , and -C(=O)R 43 Selected from; R 2 , R 3 , R 4 , and R 5 are independently selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxy, (C1-C4)alkoxycarbonylamino, carboxamido, (C1-C4)alkylaminocarbonyl, cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl, and (C1-C4)acylamino; R 6 and R 10 are independently selected from hydrogen, deuterium, halo, (C1-C3)alkyl, perfluoro(C1-C3)alkyl, hydroxy, (C1-C3)alkoxy, perfluoro(C1-C3)alkoxy, and amino; R 7 and R 9is hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, [ka] are independently selected from; R 8 is hydrogen, deuterium, halogen, halo(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, phenyl, phenoxy, benzyloxy, amino, [ka] Selected from; R 30 is (C1~C 10 ) Hydrocarbyl, amino-substituted (C1-C 10 ) hydrocarbyl, (C1-C4) hydrocarbyl substituted (C1-C 10 ) Hydrocarbyl, carboxyl substituted (C1-C 10 ) hydrocarbyl, carboxy, (C1-C6) alkoxycarbonyl, (C1-C6) alkoxycarbonylamino, methylthio, heterocyclyl, (C1-C 10 ) Oxaalkyl, CHR 44 NHR 45 and guanidine; R 40 and R 41 are independently selected from hydrogen, (C1-C6)hydrocarbyl; R 42 is (C1-C5) alkyl; R 43 is (C1-C3) alkyl, R 44 is selected from any naturally occurring amino acid side chain; R 45 is selected from H, methyl, and (C1-C4)alkoxycarbonyl; R 50 is H or (C1-C3) alkyl. Methods are provided for selecting a subject for treatment with The method includes measuring a baseline concentration of CD14+CD16+ myeloid cells in a biological sample containing circulating myeloid cells from the subject, comparing the baseline concentration of circulating CD14+CD16+ myeloid cells to a predetermined threshold concentration, and selecting the patient for treatment if the patient's baseline concentration of CD14+CD16+ myeloid cells is greater than the predetermined threshold, thereby indicating a circulating myeloid cell inflammatory phenotype.
[0006] In a further embodiment, the present invention provides a method for deselecting a subject from treatment if the baseline concentration of circulating CD14+CD16+ myeloid cells is lower than a predetermined threshold. A lower baseline concentration of circulating CD14+CD16+ myeloid cells compared to the predetermined threshold indicates a non-inflammatory phenotype of circulating myeloid cells.
[0007] In some embodiments of the method, the predetermined threshold is the concentration of circulating CD14+CD16+ myeloid cells in a biological sample containing circulating myeloid cells from a healthy individual.
[0008] In some embodiments of the methods, the patient has amyotrophic lateral sclerosis (ALS).
[0009] In a further aspect, a method is provided that further comprises administering to a subject selected for treatment a therapeutically effective amount of a compound of formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof.
[0010] In some embodiments of the method, the therapeutically effective amount is an amount sufficient to suppress the inflammatory phenotype of circulating myeloid cells.
[0011] In some embodiments of the method, the subject selected for treatment with a compound of Formula I, or a salt, hydrate, deuterated analog, or fluorinated analog, has not been previously diagnosed with, but is at risk for developing, neuroinflammation.
[0012] In some embodiments of the method, the subject selected for treatment with a compound of Formula I, or a salt, hydrate, deuterated analog, or fluorinated analog, has not been previously diagnosed with a neurodegenerative disease, but is at risk for developing it.
[0013] In some embodiments of the methods, the subject has at least one ApoE4 allele.
[0014] In some embodiments of the methods, the subject has a family history of a neurodegenerative disease.
[0015] In some embodiments of the methods, the subject has mild cognitive impairment.
[0016] In some embodiments of the methods, the subject has a TREM2 heterozygous or homozygous mutation.
[0017] In some embodiments of the method, the subject has amyloid-β (Aβ) or tau protein positive in cerebrospinal fluid (CSF).
[0018] In some embodiments of the methods, the subject has a positive amyloid-β (Aβ) PET scan.
[0019] In some embodiments of the method, the subject has a GRN heterozygous or homozygous mutation. In some embodiments of the method, the subject has a reduced level of progranulin.
[0020] In some embodiments of the method, the subject selected for treatment with a compound of Formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof, has not been previously diagnosed with a cognitive disorder, but is at least 40 years old. In some embodiments, the subject is at least 45 years old. In some embodiments, the subject is at least 50 years old. In some embodiments, the subject is at least 55 years old. In some embodiments, the subject is at least 60 years old. In some embodiments, the subject is at least 65 years old. In some embodiments, the subject is at least 70 years old. In some embodiments, the subject is at least 75 years old. In some embodiments, the subject is at least 80 years old. In some embodiments, the subject is at least 85 years old.
[0021] In another embodiment, a method is provided for treating a subject who has not been previously diagnosed with, but is at risk of developing, a neuroinflammatory and / or neurodegenerative disease, the method comprising: a) selecting a patient for treatment by the method described above; b) administering to the subject selected for treatment at least a first dose of a compound of formula I [ka] or a salt, hydrate, deuterated analog, or fluorinated analog thereof [In the formula, Ar is [ka] and; W 1 is NR 1 , O, and S, or W 9 If N, then W 1 In addition, CR 50 It may be; W 2 CR 2 or N; W 3 CR 3 or N; W 4 CR4 or N; W 5 CR 5 or N; W 6 CR 6 or N; W 7 CR 7 or N; W 8 CR 8 or N; W 9 is C or W 1 CR 50 If W 9 may be N; R 1 is H, (C1-C3) alkyl, -CH2OC(=O)R 30 , -CH2OP(=O)OR 40 OR 41 , -C(=O)OR 42 , and -C(=O)R 43 Selected from; R 2 , R 3 , R 4 , and R 5 are independently selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxy, (C1-C4)alkoxycarbonylamino, carboxamido, (C1-C4)alkylaminocarbonyl, cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl, and (C1-C4)acylamino; R 6 and R 10are independently selected from hydrogen, deuterium, halo, (C1-C3)alkyl, perfluoro(C1-C3)alkyl, hydroxy, (C1-C3)alkoxy, perfluoro(C1-C3)alkoxy, and amino; R 7 and R 9 is hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, [ka] are independently selected from; R 8 is hydrogen, deuterium, halogen, halo(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, phenyl, phenoxy, benzyloxy, amino, [ka] Selected from; R 30 is (C1~C 10 ) Hydrocarbyl, amino-substituted (C1-C 10 ) hydrocarbyl, (C1-C4) hydrocarbyl substituted (C1-C 10 ) Hydrocarbyl, carboxyl substituted (C1-C 10 ) hydrocarbyl, carboxy, (C1-C6) alkoxycarbonyl, (C1-C6) alkoxycarbonylamino, methylthio, heterocyclyl, (C1-C 10 ) Oxaalkyl, CHR 44 NHR 45 and guanidine; R 40 and R 41 are independently selected from hydrogen, (C1-C6)hydrocarbyl; R 42 is (C1-C5) alkyl; R 43 is (C1-C3) alkyl, R 44is selected from any naturally occurring amino acid side chain; R 45 is selected from H, methyl, and (C1-C4)alkoxycarbonyl; R 50 is H or (C1-C3) alkyl. and administering Includes.
[0022] In some embodiments, additional methods are provided for treating a subject who has not been previously diagnosed with, but is at risk for developing, a neuroinflammatory and / or neurodegenerative disease. The methods include: c) determining a post-administration concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from the subject; d) comparing the subject's post-administration concentration to the subject's baseline concentration; e) administering multiple subsequent doses of the same or greater amount if the post-dose concentration is less than the baseline concentration; Further includes:
[0023] In some embodiments, additional methods are provided for treating a subject who has not been previously diagnosed with, but is at risk for developing, a neuroinflammatory and / or neurodegenerative disease. The methods include: f) if the post-dose concentration is not lower than the baseline blood concentration, repeating steps (a)-(d) with successive increasing doses of a compound of formula I until the subject's post-dose concentration of circulating CD14+CD16+ myeloid cells is lower than the subject's baseline concentration or a pre-determined maximum dose of the compound is achieved. Further includes:
[0024] In some embodiments, additional methods are provided for treating a subject who has not been previously diagnosed with, but is at risk for developing, a neuroinflammatory and / or neurodegenerative disease. The methods include: g) removing the subject from further treatment if the post-injection concentration of CD14+CD16+ myeloid cells is not lower than the patient's baseline concentration. Further includes:
[0025] In another embodiment, a method is provided for treating a subject who has not been previously diagnosed with a cognitive disorder but is at least 40 years of age. The method comprises: a) selecting a patient for treatment according to the method of claim 1; b) administering to the subject selected for treatment at least a first dose of a compound of formula I [ka] or a salt, solvate, hydrate, deuterated analog, or fluorinated analog of the compound of formula (I) or (II), wherein Ar is [ka] and; W 1 is NR 1 , O, and S, or W 9 If N, then W 1 In addition, CR 50 It may be; W 2 CR 2 or N; W 3 CR 3 or N; W 4 CR 4 or N; W 5 CR 5 or N; W 6 CR 6 or N; W 7 CR 7 or N; W 8 CR 8 or N; W 9 is C or W 1 CR 50 If W 9may be N; R 1 is H, (C1-C3) alkyl, -CH2OC(=O)R 30 , -CH2OP(=O)OR 40 OR 41 , -C(=O)OR 42 , and -C(=O)R 43 Selected from; R 2 , R 3 , R 4 , and R 5 are independently selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxy, (C1-C4)alkoxycarbonylamino, carboxamido, (C1-C4)alkylaminocarbonyl, cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl, and (C1-C4)acylamino; R 6 and R 10 are independently selected from hydrogen, deuterium, halo, (C1-C3)alkyl, perfluoro(C1-C3)alkyl, hydroxy, (C1-C3)alkoxy, perfluoro(C1-C3)alkoxy, and amino; R 7 and R 9 is hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, [ka] are independently selected from; R 8is hydrogen, deuterium, halogen, halo(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, phenyl, phenoxy, benzyloxy, amino, [ka] Selected from; R 30 is (C1~C 10 ) Hydrocarbyl, amino-substituted (C1-C 10 ) hydrocarbyl, (C1-C4) hydrocarbyl substituted (C1-C 10 ) Hydrocarbyl, carboxyl substituted (C1-C 10 ) hydrocarbyl, carboxy, (C1-C6) alkoxycarbonyl, (C1-C6) alkoxycarbonylamino, methylthio, heterocyclyl, (C1-C 10 ) Oxaalkyl, CHR 44 NHR 45 and guanidine; R 40 and R 41 are independently selected from hydrogen, (C1-C6)hydrocarbyl; R 42 is (C1-C5) alkyl; R 43 is (C1-C3) alkyl, R 44 is selected from any naturally occurring amino acid side chain; R 45 is selected from H, methyl, and (C1-C4)alkoxycarbonyl; R 50 is H or (C1-C3) alkyl.
[0026] In some embodiments, additional methods are provided for treating a subject who has not been previously diagnosed with a cognitive disorder, but who is at least 40 years of age. The methods include: c) determining a post-administration concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from the subject; d) comparing the subject's post-administration concentration to the subject's baseline concentration; e) administering multiple subsequent doses of the same or greater amount if the post-dose concentration is less than the baseline concentration; Further includes:
[0027] In some embodiments, additional methods are provided for treating a subject who has not been previously diagnosed with a cognitive disorder, but who is at least 40 years of age. The methods include: f) if the post-dose concentration is not lower than the baseline blood concentration, repeating steps (a)-(d) with successively increasing doses of the compound of formula I until the subject's post-dose concentration of circulating CD14+CD16+ myeloid cells is lower than the subject's baseline concentration or a pre-determined maximum dose of the compound is achieved. Further includes:
[0028] In some embodiments, additional methods are provided for treating a subject who has not been previously diagnosed with a cognitive disorder, but who is at least 40 years of age. The methods include: g) removing the subject from further treatment if the post-administration concentration of CD14+CD16+ myeloid cells is not lower than the patient's baseline concentration. Further includes:
[0029] In another aspect, a method is provided for treating a subject having an inflammatory phenotype of circulating myeloid cells, the method comprising: A subject is administered a therapeutically effective amount of a compound of formula I [ka] or a salt, solvate, hydrate, deuterated analog, or fluorinated analog of the compound of formula (I) or (II), wherein Ar is [ka] and; W 1 is NR 1, O, and S, or W 9 If N, then W 1 In addition, CR 50 It may be; W 2 CR 2 or N; W 3 CR 3 or N; W 4 CR 4 or N; W 5 CR 5 or N; W 6 CR 6 or N; W 7 CR 7 or N; W 8 CR 8 or N; W 9 is C or W 1 CR 50 If W 9 may be N; R 1 is H, (C1-C3) alkyl, -CH2OC(=O)R 30 , -CH2OP(=O)OR 40 OR 41 , -C(=O)OR 42 , and -C(=O)R 43 Selected from; R 2 , R 3 , R 4 , and R 5are independently selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxy, (C1-C4)alkoxycarbonylamino, carboxamido, (C1-C4)alkylaminocarbonyl, cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl, and (C1-C4)acylamino; R 6 and R 10 are independently selected from hydrogen, deuterium, halo, (C1-C3)alkyl, perfluoro(C1-C3)alkyl, hydroxy, (C1-C3)alkoxy, perfluoro(C1-C3)alkoxy, and amino; R 7 and R 9 is hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, [ka] are independently selected from; R 8 is hydrogen, deuterium, halogen, halo(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, phenyl, phenoxy, benzyloxy, amino, [ka] Selected from; R 30 is (C1~C 10 ) Hydrocarbyl, amino-substituted (C1-C 10 ) hydrocarbyl, (C1-C4) hydrocarbyl substituted (C1-C 10) Hydrocarbyl, carboxyl substituted (C1-C 10 ) hydrocarbyl, carboxy, (C1-C6) alkoxycarbonyl, (C1-C6) alkoxycarbonylamino, methylthio, heterocyclyl, (C1-C 10 ) Oxaalkyl, CHR 44 NHR 45 and guanidine; R 40 and R 41 are independently selected from hydrogen, (C1-C6)hydrocarbyl; R 42 is (C1-C5) alkyl; R 43 is (C1-C3) alkyl, R 44 is selected from any naturally occurring amino acid side chain; R 45 is selected from H, methyl, and (C1-C4)alkoxycarbonyl; R 50 is H or (C1-C3) alkyl; method.
[0030] In some embodiments, additional methods are provided for treating a subject having an inflammatory phenotype of circulating myeloid cells. The methods include: b) determining a post-administration concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from the subject; c) comparing the subject's post-administration concentration to the subject's baseline concentration; d) administering multiple subsequent doses of the same or greater amount if the post-dose concentration is less than the baseline concentration; Further includes:
[0031] In some embodiments, additional methods are provided for treating a subject having an inflammatory phenotype of circulating myeloid cells. The methods include: e) if the post-dose concentration is not lower than the baseline blood concentration, repeating steps (a)-(c) with successively increasing doses of the compound of formula I until the subject's post-dose concentration of circulating CD14+CD16+ monocytes is lower than the subject's baseline concentration or a pre-determined maximum dose of the compound is achieved. Further includes:
[0032] In some embodiments, additional methods are provided for treating a subject having an inflammatory phenotype of circulating myeloid cells. The methods include: g) removing the subject from further treatment if the post-administration concentration of CD14+CD16+ myeloid cells is not lower than the patient's baseline concentration. Further includes:
[0033] In some embodiments of the method, the circulating CD14+CD16+ myeloid cells are monocytes.
[0034] In some embodiments of the method, the compound is administered orally.
[0035] In some embodiments of the method, the administered dose is about 200 mg to about 800 mg. In some embodiments of the method, the administered dose is about 300 mg to about 700 mg. In some embodiments of the method, the administered dose range is about 400 mg to about 600 mg.
[0036] In some embodiments of the method, the dose is 400 mg, 450 mg, or 500 mg.
[0037] In some embodiments of the method, the dose is administered daily. In some embodiments of the method, the dose is administered once a day as a single, undivided dose.
[0038] In some embodiments of the methods, the biological sample is whole blood.
[0039] In some embodiments of the method, the concentration of CD14+CD16+ circulating myeloid cells is determined by measuring at least one of CD14 and CD16 polypeptides, CD14 and CD16 mRNA, and CD14 and CD16 cDNA in the biological sample. In some embodiments of the method, the concentration of CD14+CD16+ monocytes is determined by measuring CD14 and CD16 polypeptides. In some embodiments of the method, the concentration of CD14+CD16+ monocytes in the sample is measured by using one or more reagents that specifically bind to CD14 or CD16 polypeptides. In some embodiments of the method, the reagents are selected from the group consisting of antibodies, antibody derivatives, and antigen-binding antibody fragments. In some embodiments of the method, the concentration of CD14+CD16+ monocytes is determined by flow cytometry.
[0040] In some embodiments of the method, the level of CD14 and CD16 polypeptides is determined by detecting the amount of transcribed polynucleotide or a part thereof. In some embodiments of the method, the transcribed polynucleotide is mRNA. In some embodiments of the method, the transcribed polynucleotide is cDNA. In some embodiments of the method, the detection further comprises amplifying the transcribed polynucleotide or a part thereof.
[0041] In some embodiments of the method, the compound is Compound I [ka] and Compound II [ka] or a pharma- ceutically acceptable salt, hydrate, or deuterated analog thereof.
[0042] In some embodiments of the method, the compound is Compound I or a pharma- ceutically acceptable salt, hydrate, or deuterated analog thereof.
[0043] In some embodiments of the method, the compound is Compound II or a pharma- ceutically acceptable salt, hydrate, or deuterated analog thereof.
[0044] In some embodiments of the method, the compound or a salt, hydrate, deuterated analog, or fluorinated analog is administered in a suspension, solution, or in a solid dosage form.
[0045] In some embodiments of the method, the solid dosage form is a capsule.In some embodiments of the method, the solid dosage form is a tablet.
[0046] 4. Brief description of the drawings These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description and accompanying drawings: [Brief description of the drawings]
[0047] [Figure 1-1] Figure 1A shows the gating procedure used in FACS assays of mouse LPS-induced blood samples to detect and quantify Ly6Chi cells. Figure 1B shows that in vitro incubation of wild-type mouse blood samples with LPS increases the percentage of Ly6Chi cells, and incubation with TQS-168 suppresses this increase in inflammatory myeloid cells. Figure 1C illustrates the experimental design. [Figure 1-2] Figure 1A shows the gating procedure used in FACS assays of mouse LPS-induced blood samples to detect and quantify Ly6Chi cells. Figure 1B shows that in vitro incubation of wild-type mouse blood samples with LPS increases the percentage of Ly6Chi cells, and incubation with TQS-168 suppresses this increase in inflammatory myeloid cells. Figure 1C illustrates the experimental design.
[0048] [Diagram 2]Figure 2A plots the plasma concentration of TQS-168 over time following a single oral dose of 50 mg / mL TQS-168 in mice. Figure 2B is a timeline depicting the protocol of the SOD1 mouse study.
[0049] [Diagram 3] Figure 3A is a bar graph showing that TQS-168 reduces the fraction of inflammatory monocytes in SOD1 mice. Figure 3B is a bar graph showing that TQS-168 regulates plasma levels of anti-inflammatory and pro-inflammatory cytokines in SOD1 mice.
[0050] [Figure 4] Figure 4A compares the survival percentage vs. time after 110 days in SOD1 mice treated with an oral dose of 50 mg / kg TQS-168, and Figure 4B compares the survival age in days for the two populations of SOD1 mice treated with an oral dose of 50 mg / kg TQS-168.
[0051] [Figure 5-1] Figure 5A is a FACS assay showing that the percentage of CD14+CD16+ monocytes in peripheral blood samples from ALS patients is higher than that in peripheral blood samples from healthy normal subjects. Figure 5B outlines the experimental protocol for evaluating the effect of TQS-168 on the inflammatory phenotype of circulating myeloid cells in peripheral blood samples from ALS patients and control healthy donors, and Figure 5C is a bar graph showing the results of a 4-hour ex vivo incubation of peripheral blood samples with increasing concentrations of TQS-168, demonstrating that TQS-168 dose-dependently reduces the percentage of CD14+CD16+ cells in whole blood from ALS patients. [Figure 5-2]Figure 5A is a FACS assay showing that the percentage of CD14+CD16+ monocytes in peripheral blood samples from ALS patients is higher than that in peripheral blood samples from healthy normal subjects. Figure 5B outlines the experimental protocol for evaluating the effect of TQS-168 on the inflammatory phenotype of circulating myeloid cells in peripheral blood samples from ALS patients and control healthy donors, and Figure 5C is a bar graph showing the results of a 4-hour ex vivo incubation of peripheral blood samples with increasing concentrations of TQS-168, demonstrating that TQS-168 dose-dependently reduces the percentage of CD14+CD16+ cells in whole blood from ALS patients. [Figure 5-3] Figure 5A is a FACS assay showing that the percentage of CD14+CD16+ monocytes in peripheral blood samples from ALS patients is higher than that in peripheral blood samples from healthy normal subjects. Figure 5B outlines the experimental protocol for evaluating the effect of TQS-168 on the inflammatory phenotype of circulating myeloid cells in peripheral blood samples from ALS patients and control healthy donors, and Figure 5C is a bar graph showing the results of a 4-hour ex vivo incubation of peripheral blood samples with increasing concentrations of TQS-168, demonstrating that TQS-168 dose-dependently reduces the percentage of CD14+CD16+ cells in whole blood from ALS patients. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0052] 5. Detailed Description of the Invention 5.1. Definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0053] If the concentration of CD14+CD16+ myeloid cells in the sample taken from the peripheral circulation of the subject exceeds a predetermined threshold concentration, the individual subject has "inflammatory phenotype of circulating myeloid cells". If the concentration of CD14+CD16+ myeloid cells in the sample taken from the peripheral circulation of the subject does not exceed a predetermined threshold concentration, as further defined below, the individual subject has "non-inflammatory phenotype of circulating myeloid cells". The phrase "suppression of inflammatory phenotype of circulating myeloid cells" refers to lowering the concentration of CD14+CD16+ cells in the sample taken from the peripheral circulation of the subject below a predetermined threshold concentration.
[0054] The terms "individual," "host," and "subject" are used interchangeably and refer to the animal being treated, including, but not limited to, humans and non-human primates; rodents, including rats and mice; cattle; horses; sheep; cats; and dogs. "Patient" refers to a human subject.
[0055] The terms "treating", "treatment" and grammatical variations thereof are used in the broadest sense as understood in the clinical field. Thus, these terms do not require a cure or complete remission of a disease, but encompass obtaining any clinically desired pharmacological and / or physiological effect. Unless otherwise specified, "treating" and "treatment" do not encompass prophylaxis.
[0056] The phrase "therapeutically effective amount" refers to the amount of a compound that, when administered to a mammal or other subject for treating a disease, condition, or disorder, is sufficient to effect treatment of the disease, condition, or disorder. A "therapeutically effective amount" can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject being treated.
[0057] The term "pharmaceutically acceptable salt" refers to a salt that is acceptable for administration to a subject. Examples of pharma- ceutically acceptable salts include, but are not limited to, acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate.
[0058] Other examples of pharmaceutical salts include N + , NH4 + , and NW4 - (wherein W can be a C1-C8 alkyl group), and anions of the compounds of the present disclosure in complex with the same. For therapeutic applications, salts of the compounds of the present disclosure may be pharma-ceutically acceptable. However, salts of acids and bases that are not pharma-ceutically acceptable may also be used, for example, in the preparation or purification of a pharma-ceutically acceptable compound.
[0059] Compounds included in the present compositions and methods that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. Acids that can be used to prepare pharma- ceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, hydrogen sulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts.
[0060] Compounds included in the present compositions and methods that are acidic in nature can form base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline earth metal salts, particularly the calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
[0061] The compounds included in the compositions and methods that contain basic or acidic moieties can also form pharmaceutically acceptable salts with various amino acids.The compounds of the present disclosure can contain both acidic and basic groups; for example, one amino and one carboxylic acid group.In such cases, the compounds can exist as acid addition salts, zwitterions, or base salts.
[0062] The terms "pharmaceutically acceptable excipient," "pharmaceutically acceptable diluent," "pharmaceutically acceptable carrier," and "pharmaceutically acceptable adjuvant" are used interchangeably and refer to an excipient, diluent, carrier, or adjuvant that is generally safe, non-toxic, and not biologically or otherwise undesirable and is useful in the preparation of a pharmaceutical composition, and include excipients, diluents, carriers, and adjuvants that are acceptable for veterinary use, as well as human pharmaceutical use. The phrase "pharmaceutically acceptable excipient" includes both one and more than one such excipient, diluent, carrier, and / or adjuvant.
[0063] In general, a reference or description of a particular element, such as hydrogen or H, is intended to include all isotopes of that element. For example, if an R group is defined to include hydrogen or H, it also includes deuterium and tritium. Thus, tritium, 14 C. 32 P and 35 Compounds containing radioisotopes such as S are within the scope of the present technology. Procedures for incorporating such labels into the compounds of the present technology will be readily apparent to those of skill in the art based on the disclosure herein.
[0064] Unless specific stereochemistry is explicitly stated, all chiral, diastereomeric and racemic forms of compound are intended.Therefore, the compounds described herein include the optical isomers enriched or resolved at any or all asymmetric atoms as is clear from the description.The racemic mixture of R-enantiomer and S-enantiomer, as well as the enantioenriched stereoisomeric mixture containing R- and S-enantiomer, as well as individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and all of these stereoisomers are within the scope of the present technology.
[0065] The compounds described herein may exist as solvates, particularly hydrates, and all such solvates and hydrates are intended unless otherwise specified.Hydrates may form during the preparation of the compounds or compositions containing the compounds, or hydrates may form over time due to the hygroscopic nature of the compounds.The compounds of the present technology may also exist as organic solvent solvates, including DMF, ether, and alcohol solvates, among others.The identification and preparation of any particular solvate is within the skill of a person skilled in the art of synthetic organic or medicinal chemistry.
[0066] As described herein, this text relates to various embodiments of the compounds, compositions and methods.The various embodiments described are meant to provide various examples and should not be interpreted as descriptions of alternative species.Rather, it should be noted that the descriptions of the various embodiments provided herein may be of overlapping scope.The embodiments discussed herein are merely illustrative and are not meant to limit the scope of the present technology.
[0067] 5.2. Other Interpretive Promises Ranges: Throughout this disclosure, various aspects of the invention are expressed in range format. The ranges include the recited endpoints. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as a rigid limitation on the scope of the invention. Thus, the description of a range should be interpreted as having all possible subranges specifically disclosed, as well as individual numerical values within that range. For example, the description of a range such as 1-6 should be interpreted as having specifically disclosed subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, as well as individual numerical values within that range, e.g., 1, 2, 3, 4, 5, 5.3, and 6. This is true regardless of the breadth of the range.
[0068] In this disclosure, the words "comprises," "comprising," "containing," "having," "includes," "including," and linguistic variants thereof have the meanings given to them in U.S. patent law and permit the presence of additional ingredients beyond those specifically recited.
[0069] Unless specifically stated otherwise or clear from the context, the term "or" as used herein is understood to be inclusive.
[0070] Unless specifically stated otherwise or clear from the context, as used herein, the terms "a," "an," and "the" are understood to be singular or plural. That is, the articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0071] Unless specifically stated or clear from the context, the term "about" as used herein is understood to be within normal tolerances in the art, e.g., within 2 standard deviations from the mean, and is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and even more preferably ±0.1% from the stated value. When a percentage is presented in relation to the amount of an ingredient or material in a composition, the percentage should be understood to be a percentage by weight unless otherwise stated or understood from the context.
[0072] It is to be understood that two or more steps or actions may be conducted simultaneously.
[0073] 5.3. Summary of experimental observations As detailed in the experimental examples of the present disclosure, the inventors have demonstrated that SOD1 mice, a model for amyotrophic lateral sclerosis (ALS), have approximately 5-fold higher percentage of Ly6C in their peripheral circulation than do wild-type mice. hi Treatment with 50 mg / kg TQS-168 administered by oral gavage every 3 days from days 70 to 90 reduced circulating Ly6C in SOD1 mice. hi SOD1 mice that received TQS-168 by oral gavage survived longer than mice that received vehicle alone.
[0074] Next, we demonstrated that ALS patients also exhibited an abnormally high percentage of CD14+CD16+ monocytes in the peripheral circulation when compared to healthy controls. We further demonstrated that ex vivo incubation of blood samples from ALS patients with TQS-168 for 4 hours dose-dependently reduced the percentage of intermediate (CD14+CD16+) monocytes in the samples, with the highest concentration of TQS-168, 30 μM, reducing CD14+CD16+ monocytes from 1.5% to less than 1%.
[0075] Collectively, these data indicate that circulating inflammatory myeloid cells such as CD14+CD16+ monocytes in human patients are clinically accessible surrogate markers for the action of 2-arylbenzimidazoles such as TQS-168 in treating neuroinflammatory and neurodegenerative disorders. The data indicate that circulating inflammatory myeloid cells such as CD14+CD16+ monocytes can be used to identify and select patients for treatment with TQS-168 and other 2-aryl-benzimidazoles, and can be used to monitor and titrate treatment of such patients, including human ALS patients.
[0076] 5.4. Methods of Selecting Subjects for Treatment with 2-Arylbenzimidazole Compounds Thus, in a first aspect, there is provided a method for selecting a subject for treatment with a particular therapeutic 2-arylbenzimidazole compound, or a salt, hydrate, deuterated analog, or fluorinated analog thereof, as described in Section 5.9 herein. The method comprises: a) measuring a baseline concentration of CD14+CD16+ myeloid cells in a biological sample containing circulating myeloid cells from a subject; b) comparing the baseline concentration of circulating CD14+CD16+ myeloid cells to a predetermined threshold concentration; c) selecting the patient for treatment if the patient's baseline concentration of CD14+CD16+ myeloid cells is greater than a predetermined threshold, thereby indicating a circulating myeloid cell inflammatory phenotype. Includes.
[0077] In some embodiments, the CD14+CD16+ circulating myeloid cells are CD14+CD16+ circulating monocytes.
[0078] In typical embodiments, the biological sample is a whole blood sample taken from a subject. In some embodiments, the biological sample is a cellular fraction derived from a whole blood sample.
[0079] In some embodiments of the method, the predetermined threshold is the concentration of circulating CD14+CD16+ myeloid cells in the biological sample containing circulating myeloid cells from a healthy individual.In a typical embodiment, the biological sample that provides the predetermined threshold is a whole blood sample.In some embodiments, the biological sample that provides the predetermined threshold is a fraction derived from a whole blood sample of a healthy individual.
[0080] In some embodiments of the method, the healthy subject or individual is not diagnosed with neurodegenerative disease.In some embodiments of the method, the healthy subject is not diagnosed with neurodegenerative disease selected from amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), dementia with Lewy bodies, vascular or multi-infarct dementia, or frontotemporal dementia (FTD), Parkinson's disease, Huntington's disease, demyelinating disease, and multiple sclerosis (MS).In some embodiments of the method, the healthy subject is not diagnosed with ALS.
[0081] In some embodiments of the method, the predetermined threshold is the mean concentration of circulating CD14+CD16+ myeloid cells in a biological sample containing circulating myeloid cells from a healthy population. In some embodiments of the method, the predetermined threshold is the median concentration of circulating CD14+CD16+ myeloid cells in a biological sample containing circulating myeloid cells from a healthy population. In some embodiments of the method, the predetermined threshold is the maximum value of the range of percentage values of circulating CD14+CD16+ myeloid cells in healthy subjects.
[0082] In some embodiments of the method, the predetermined threshold is a single value. In some embodiments of the method, the predetermined threshold is a range of values.
[0083] In some embodiments of the method, the predetermined threshold is the concentration of circulating CD14+CD16+ myeloid cells relative to total circulating myeloid cells. In various embodiments, the concentration is 0.85%, 0.86%, 0.88%, 0.89%, 0.90%, 0.91%, 0.92%, 0.93%, 0.94%, 0.95%, 0.96%, 0.97%, 0.98%, 0.99%, 1.0%, 1.01%, 1.02%, 1.03%, 1.04%, 1.05%, 1.06%, 1.07%, 1.08%, 1.09%, 1.10%, 1.11%, 1.12%, 1.13%, 1.14%, 1.15%, 1.16%, 1.17%, 1.18%, 1.19%, 1.20%, 1.21%, 1.22%, 1.23%, 1.24%, 1.25%, 1.26%, 1.27%, 1.28%, 1.29%, 1.30%, 1.31%, 1.32%, 1.33%, 1.34%, 1.35%, 1.36%, 1.37%, 1.38%, 1.39%, 1.40%, 1.41%, 1.42%, 1.43%, 1.44%, 1.45%, 1.46%, 1.47%, 1.48%, 1.49%, 1.50%, 1.51%, 1.52%, 1.53%, 1.54%, 1.55%, 1.56%, 1.57%, 1.58%, 1.59%, 1.60%, 1.61%, 1.62%, 1.63%, 1.64%, 1.65%, 1.66%, 1.67%, 1.68%, 1.69%, or 1.70%.
[0084] In some embodiments of the method, the predetermined threshold is higher than the median across a healthy population of males between the ages of at least 18 years. In some further embodiments of the method, the males are between the ages of 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 102, 104, 105, 106, 107, 108, 109, 109, 109, 102, 103, 104, 105, 106, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 years of age. In some further embodiments of the methods, the predetermined threshold is greater than the median across a healthy population of men aged at least between 18 and 40 years of age.
[0085] In some embodiments of the method, the predetermined threshold is higher than the average value across a healthy population of males between the ages of at least 18. In some further embodiments of the method, the male is between the ages of 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 years of age. In some further embodiments of the methods, the predetermined threshold is greater than the average for an entire healthy population of men aged at least between 18 and 40 years of age.
[0086] In some embodiments of the method, the predetermined threshold is higher than the median across a healthy population of women between the ages of at least 18. In some further embodiments of the method, the women are 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 102, 104, 105, 106, 107, 108, 109, 109, 109, 102, 103, 104, 105, 106, 107, 108 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 years of age. In some further embodiments of the methods, the predetermined threshold is greater than the median across a healthy population of women aged at least between 18 and 40 years of age.
[0087] In some embodiments of the method, the predetermined threshold is higher than the average value for the entire healthy population of women between the ages of at least 18. In some further embodiments of the method, the woman is at least 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 102, 104, 105, 106, 107, 108, 109, 109, 109, 102, 103, 104, 105, 106, 107, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 years old. In some further embodiments of the method, the predetermined threshold is higher than the average for an entire healthy population of women aged at least between 18 and 40 years old.
[0088] In some embodiments of the method, the healthy population is a mix of males and females. In some embodiments of the method, the healthy population is a mix of males and females who are at least 18 years old. In some further embodiments of the method, the males and females are 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 110 6, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 years old. In some embodiments of the methods, the healthy population is a mix of males and females aged at least between 18 and 40 years old.
[0089] In some embodiments of the method, a therapeutically effective amount of a compound of formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof, as described in Section 5.9 herein, is administered to a subject selected for treatment. In some embodiments of the method, the therapeutically effective amount is an amount sufficient to suppress the inflammatory phenotype of circulating myeloid cells. In some embodiments of the method, the therapeutically effective amount is effective to suppress the synthesis, and optionally secretion, of one or more inflammatory cytokines when circulating inflammatory myeloid cells are exposed to LPS in vitro. In some embodiments, the one or more inflammatory cytokines are selected from IFN-γ, IL-6, TNF-α, MCP-1, and IL12.
[0090] In some embodiments of the method, the subject selected for treatment with a compound of Formula I, or a salt, hydrate, deuterated analog, or fluorinated analog, has not been previously diagnosed with neuroinflammation, but is at risk for developing it.
[0091] In some embodiments of the method, the subject selected for treatment with a compound of Formula I, or a salt, hydrate, deuterated analog, or fluorinated analog, has not been previously diagnosed with a neurodegenerative disease, but is at risk of developing it.
[0092] In some embodiments of the method, the neurodegenerative disease, the subject has not been previously diagnosed with, but is at risk of developing, amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), dementia with Lewy bodies, vascular or multi-infarct dementia, or frontotemporal dementia (FTD), Parkinson's disease, Huntington's disease, a demyelinating disease, or multiple sclerosis (MS).
[0093] In some embodiments of the method, the subject has at least one ApoE4 allele. In certain embodiments of the method, the subject has two ApoE4 alleles. In some certain embodiments of the method, the method further comprises the preceding step of detecting the presence of the ApoE4 allele in the subject.
[0094] In certain embodiments of the method, the subject has a family history of neurodegenerative disease.In some particular embodiments of the method, the neurodegenerative disease in the subject's family history is amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), dementia with Lewy bodies, vascular or multi-infarct dementia, or frontotemporal dementia (FTD), Parkinson's disease, Huntington's disease, demyelinating disease, or multiple sclerosis (MS).
[0095] In some embodiments of the method, the subject has mild cognitive impairment.In certain embodiments, the diagnosis of MCI is carried out using Short Test of Mental Status, Montreal Cognitive Assessment (MoCA) or Mini-Mental State Examination (MMSE).
[0096] In some embodiments of the method, the subject has a TREM2 heterozygous or homozygous mutation. In some specific embodiments of the method, the subject has a TREM2 heterozygous mutation. In some specific embodiments of the method, the subject has a TREM2 homozygous mutation. In some embodiments of the method, the TREM2 variant exhibits a partial loss of function of the TREM2 protein. In some embodiments of the method, the TREM2 variant exhibits an abnormal function of the TREM2 protein. In some embodiments of the method, the TREM2 variant alters the behavior of microglial cells, including their response to amyloid plaques. In some specific embodiments of the method, the method further comprises a preceding step of detecting the presence of a TREM2 heterozygous or homozygous mutation in the subject.
[0097] In some embodiments of the method, the subject has a PSEN1 heterozygous or homozygous mutation. In some specific embodiments of the method, the subject has a PSEN1 heterozygous mutation. In some specific embodiments of the method, the subject has a PSEN1 homozygous mutation. In some embodiments of the method, the PSEN1 variant exhibits partial loss of function of the PSEN1 protein. In some embodiments of the method, the PSEN1 variant exhibits abnormal function of the PSEN1 protein. In some embodiments of the method, the subject with the PSEN1 variant exhibits increased amyloid plaque production. In some specific embodiments of the method, the method further comprises a preceding step of detecting the presence of a PSEN1 heterozygous or homozygous mutation in the subject.
[0098] In some embodiments of the method, the subject has amyloid-β (Aβ) or tau protein positive in cerebrospinal fluid (CSF). In some embodiments of the method, the subject has abnormal levels of total tau and phosphorylated tau in CSF.
[0099] In some embodiments of the methods, the subject had a positive amyloid-β (Aβ) PET scan prior to treatment.
[0100] In some embodiments of the method, the subject has been determined prior to treatment to have at least one of: (i) a decreased level of plasma Aβ42; (ii) an increased level of plasma Aβ40; (iii) a decreased ratio of plasma Aβ42 / Aβ40; (iv) an increased level of plasma neurofilament light chain (NFL); and (v) an increased level of plasma neurogranin, when compared to a healthy control population without a neurodegenerative disease.
[0101] In some embodiments of the method, the subject had a positive Tau protein PET scan prior to treatment. In some particular embodiments of the method, the subject has been determined prior to treatment to have an abnormal pattern of Tau based on Tau PET imaging.
[0102] In some embodiments of the method, the subject has GRN heterozygous or homozygous mutation. In some specific embodiments of the method, the subject has GRN heterozygous mutation. In some specific embodiments of the method, the subject has GRN homozygous mutation. In some specific embodiments of the method, the GRN variant exhibits partial loss of function of GRN protein. In some specific embodiments of the method, the GRN variant exhibits abnormal function of GRN protein. In some specific embodiments of the method, the method further comprises the preceding step of detecting the presence of GRN heterozygous or homozygous mutation in the subject.
[0103] In some embodiments of the method, the subject has reduced progranulin levels. In some embodiments of the method, the subject has reduced progranulin levels.
[0104] In some embodiments of the method, the subject selected for treatment with the compound of formula I or its salt, hydrate, deuterated analog, or fluorinated analog is at least 40 years old, but has not been previously diagnosed with cognitive impairment. In some embodiments of the method, the subject is at least 45 years old. In some embodiments of the method, the subject is at least 50 years old. In some embodiments of the method, the subject is at least 55 years old. In some embodiments of the method, the subject is at least 60 years old. In some embodiments of the method, the subject is at least 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 years old.
[0105] In some embodiments of the method, the subject is removed from treatment if the baseline concentration of circulating CD14+CD16+ myeloid cells is below a predetermined threshold, thereby indicating a circulating myeloid cell non-inflammatory phenotype.
[0106] 5.5. Methods of Treating Subjects Not Previously Diagnosed with, but at Risk for, Developing a Neuroinflammatory and / or Neurodegenerative Disease In another aspect, a method is provided for treating a subject who has not been previously diagnosed with a neuroinflammatory and / or neurodegenerative disease but is at risk of developing the same.The method includes the steps of selecting a patient for treatment by the method described in Section 5.4 herein; and administering to the subject selected for treatment at least a first dose of a 2-arylbenzimidazole compound of formula I, or its salt, hydrate, deuterated analog, or fluorinated analog, as described in Section 5.9 herein.
[0107] In certain embodiments, the method further comprises determining a post-administration concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from the subject, comparing the subject's post-administration concentration to the subject's baseline concentration, and administering multiple subsequent doses of the same or higher amounts if the post-administration concentration is lower than the baseline concentration.
[0108] In certain embodiments, the method further comprises repeating the steps of determining a post-dose concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from the subject, if the post-dose concentration is not lower than the baseline blood concentration, comparing the subject's post-dose concentration to the subject's baseline concentration, and if the post-dose concentration is lower than the baseline concentration, administering one or more successive increasing doses of a compound of formula I until the subject's post-dose concentration of circulating CD14+CD16+ myeloid cells is lower than the subject's baseline concentration or a predetermined maximum dose of the compound is achieved.
[0109] In some further particular embodiments of the methods, the methods further comprise the step of discontinuing the subject from further treatment if the post-administration concentration of CD14+CD16+ myeloid cells is not lower than the patient's baseline concentration. 5.6. Methods of Treating Subjects Who Have Not Previously Been Diagnosed with Cognitive Impairment and Are at Least 40 Years Old
[0110] In a further aspect, a method is provided for treating a subject who has not been previously diagnosed with a cognitive disorder, but who is at least 40 years of age. The method includes the steps of selecting a patient for treatment by the methods described herein in Section 5.4; and administering to the subject selected for treatment at least a first dose of a 2-arylbenzamidazole compound of formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof, as described herein in Section 5.9.
[0111] In some embodiments, the method further includes determining a post-administration concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from the subject, comparing the subject's post-administration concentration to the subject's baseline concentration, and administering multiple subsequent doses of the same or higher amount if the post-administration concentration is lower than the baseline concentration.
[0112] In some further embodiments of the method, after determining the post-administration concentration of circulating CD14+CD16+ myeloid cells in the biological sample obtained from the subject, the method further comprises comparing the subject's post-administration concentration to the subject's baseline concentration, and if the post-administration concentration is lower than the baseline concentration, administering multiple subsequent doses of the same or higher amount. In some embodiments, if the post-administration concentration is not lower than the baseline blood concentration, the method further comprises repeating the above-mentioned steps with successive increasing doses of the compound of formula I until the subject's post-administration concentration of circulating CD14+CD16+ myeloid cells is lower than the subject's baseline concentration or a predetermined maximum dose of the compound is achieved.
[0113] In some further embodiments of the method, after determining the post-dose concentration of circulating CD14+CD16+ myeloid cells in the biological sample obtained from the subject, the method further comprises the steps of comparing the subject's post-dose concentration to the subject's baseline concentration, and if the post-dose concentration is lower than the baseline concentration, administering multiple subsequent doses of the same or higher amounts, and further, if the post-dose concentration is not lower than the baseline blood concentration, repeating the above-mentioned steps with successive increasing doses of the compound of formula I until the subject's post-dose concentration of circulating CD14+CD16+ myeloid cells is lower than the subject's baseline concentration or a pre-determined maximum dose of the compound is achieved, and still further, removing the subject from further treatment if the post-dose concentration of CD14+CD16+ myeloid cells is not lower than the patient's baseline concentration.
[0114] 5.7. Methods of Treating Subjects with an Inflammatory Phenotype of Circulating Myeloid Cells In another aspect, a method is provided for treating a subject having an inflammatory phenotype of circulating myeloid cells, the method comprising administering to the subject having an inflammatory phenotype of circulating myeloid cells a therapeutically effective amount of a compound of Formula (I), or a salt, hydrate, deuterated analog, or fluorinated analog thereof, as described herein in Section 5.9.
[0115] In some embodiments of the method, the method further includes determining a post-administration concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from the subject, comparing the subject's post-administration concentration to the subject's baseline concentration, and if the post-administration concentration is lower than the baseline concentration, administering multiple subsequent doses of the same or higher amount.
[0116] In another embodiment of the method, if the post-dose concentration is not lower than the baseline blood concentration, the method further comprises the steps of determining a post-dose concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from the subject, comparing the subject's post-dose concentration to the subject's baseline concentration, and if the post-dose concentration is lower than the baseline concentration, repeating the steps of administering multiple subsequent doses of the same or higher amounts of the compound of formula I in successive increasing doses until the subject's post-dose concentration of circulating CD14+CD16+ myeloid cells is lower than the subject's baseline concentration or a predetermined maximum dose of the compound is achieved.
[0117] In another embodiment of the method, if the post-administration concentration is not lower than the baseline blood concentration, the method further comprises administering multiple successive increasing doses of the compound of formula I until the subject's post-administration concentration of circulating CD14+CD16+ myeloid cells is lower than the subject's baseline concentration or a predetermined maximum dose of the compound is achieved. If the maximum dose of the compound is achieved without the subject's post-administration concentration of circulating CD14+CD16+ myeloid cells being lower than baseline, the method may further comprise removing the subject from further treatment if the post-administration concentration of CD14+CD16+ monocytes is not lower than the patient's baseline concentration.
[0118] 5.8. Methods for assessing the efficacy of compounds in treating neurodegenerative diseases In another aspect, methods are provided for evaluating the effectiveness of a compound in treating a neurodegenerative disease, as described in the following numbered paragraphs:
[0119] 1. A method for evaluating the efficacy of a compound in treating a neurodegenerative disease in a human patient with a 2-arylbenzimidazole moiety, comprising: (a) determining a baseline expression level of one or more biomarkers in whole blood collected from a healthy human subject; (b) determining in whole blood collected from a patient suffering from one or more neurodegenerative diseases a baseline expression level of one or more of the same biomarkers utilized in step (a); (c) comparing the baseline expression of the pre-measured biomarkers in whole blood collected from healthy human subjects with baseline expression levels of the same biomarkers collected from whole blood of patients suffering from one or more neurodegenerative diseases; (d) administering the 2-arylbenzimidazole moiety to a patient suffering from one or more neurodegenerative diseases; (e) measuring post-treatment changes from baseline expression levels of the biomarkers measured in step (b); The method includes:
[0120] 2. The method of embodiment 1, wherein the 2-arylbenzimidazole moiety is selected from TQS-168 and TQS-621.
[0121] 3. The method of embodiment 1, wherein the biomarker is an inflammatory phenotype.
[0122] 4. The method of embodiment 1, wherein the inflammatory phenotype is CD14+CD16+.
[0123] 5. The method of embodiment 1, wherein the neurodegenerative disorder is one or more of the following: Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), frontotemporal degeneration (FTD), dementia with Lewy bodies (DLB), motor neuron disease (MND), and demyelinating diseases.
[0124] 6. A method of treating a neurodegenerative disease by administering to a patient a 2-arylbenzimidazole moiety, comprising titrating the compound to determine an appropriate therapeutic dosage for the patient: (a) the number of peripheral circulating CD14+ and CD16+ monocytes / macrophages; and / or (b) a decrease in the percentage of circulating CD14 and CD16 monocytes; and / or (c) Change in CD14+ / CD16+ ratio The method includes using 5.9. 2-Arylbenzimidazole Compounds of Formula (I)
[0125] In the methods described herein, the 2-arylbenzimidazole compound is a compound of formula I [ka] or a salt, hydrate, deuterated analog, or fluorinated analog thereof [In the formula, Ar is [ka] and; W 1 is NR 1 , O, and S, or W 9 If N, then W 1 In addition, CR 50 It may be; W 2 CR 2 or N; W 3 CR 3 or N; W 4CR 4 or N; W 5 CR 5 or N; W 6 CR 6 or N; W 7 CR 7 or N; W 8 CR 8 or N; W 9 is C or W 1 CR 50 If W 9 may be N; R 1 is H, (C1-C3) alkyl, -CH2OC(=O)R 30 , -CH2OP(=O)OR 40 OR 41 , -C(=O)OR 42 , and -C(=O)R 43 Selected from; R 2 , R 3 , R 4 , and R 5 are independently selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxy, (C1-C4)alkoxycarbonylamino, carboxamido, (C1-C4)alkylaminocarbonyl, cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl, and (C1-C4)acylamino; R 6 and R 10are independently selected from hydrogen, deuterium, halo, (C1-C3)alkyl, perfluoro(C1-C3)alkyl, hydroxy, (C1-C3)alkoxy, perfluoro(C1-C3)alkoxy, and amino; R 7 and R 9 is hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, [ka] are independently selected from; R 8 is hydrogen, deuterium, halogen, halo(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, phenyl, phenoxy, benzyloxy, amino, [ka] Selected from; R 30 is (C1~C 10 ) Hydrocarbyl, amino-substituted (C1-C 10 ) hydrocarbyl, (C1-C4) hydrocarbyl substituted (C1-C 10 ) Hydrocarbyl, carboxyl substituted (C1-C 10 ) hydrocarbyl, carboxy, (C1-C6) alkoxycarbonyl, (C1-C6) alkoxycarbonylamino, methylthio, heterocyclyl, (C1-C 10 ) Oxaalkyl, CHR 44 NHR 45 and guanidine; R 40 and R 41 are independently selected from hydrogen, (C1-C6)hydrocarbyl; R 42 is (C1-C5) alkyl; R 43 is (C1-C3) alkyl, R 44is selected from any naturally occurring amino acid side chain; R 45 is selected from H, methyl, and (C1-C4)alkoxycarbonyl; R 50 is H or (C1-C3) alkyl.
[0001] In some embodiments, the compound of formula I is [ka] or a salt, hydrate, deuterated analog, or fluorinated analog thereof.
[0126] In certain embodiments, the compound of formula (I) is compound 1 [ka] (also known as ZLN-005 or TQS-168), or a salt, hydrate, deuterated analog, or fluorinated analog thereof.
[0127] In certain embodiments, the compound of formula (I) is compound 4 [ka] (also known as TQS-621), or a salt, hydrate, deuterated analog, or fluorinated analog thereof.
[0128] 5.10. Measurement of circulating myeloid cells In typical embodiments of the methods described herein, the circulating CD14+CD16+ myeloid cells are monocytes.
[0129] In certain embodiments of the methods described herein, the biological sample is whole blood. In certain embodiments, the biological sample is a section or fraction of whole blood.
[0130] In certain embodiments, the concentration of CD14+CD16+ circulating myeloid cells is determined in a biological sample by measuring at least one of CD14 and CD16 polypeptides, CD14 and CD16 mRNA, and CD14 and CD16 cDNA.
[0131] In certain embodiments, the concentration of CD14+CD16+ monocytes is determined by measuring CD14 and CD16 polypeptides.
[0132] In certain embodiments, the concentration of CD14+CD16+ monocytes in a sample is measured by using one or more reagents that specifically bind to a CD14 or CD16 polypeptide.
[0133] In certain embodiments, the reagent is selected from the group consisting of an antibody, an antibody derivative, and an antigen-binding antibody fragment. In certain embodiments, the antibody, antibody derivative, or antigen-binding antibody fragment may be an IgA, IgD, IgE, IgG, or IgM antibody, including any subclass of these isotypes. In certain embodiments, the antibody is an IgG antibody.
[0134] In the methods described herein, in certain embodiments, the concentration of CD14+CD16+ monocytes is determined by flow cytometry.
[0135] In certain embodiments of the method described herein, the level of CD14 and CD16 polypeptide is determined by detecting the amount of transcribed polynucleotide or a part thereof.In certain embodiments of the method described herein, the transcribed polynucleotide is mRNA.In certain embodiments of the method described herein, the transcribed polynucleotide is cDNA.In certain embodiments of the method described herein, the detection further comprises amplifying transcribed polynucleotide or a part thereof.
[0136] 5.11. Dosage regimens and dosage forms In certain embodiments of the methods described herein, the compound of formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof, is administered orally.
[0137] In some embodiments, the compound is administered as a tablet.
[0138] In certain embodiments, the dose administered is from about 200 mg to about 800 mg.
[0139] In certain embodiments of the methods described herein, the dosage administered is from about 300 mg to about 700 mg.
[0140] In certain embodiments of the methods described herein, the dosage administered is from about 400 mg to about 600 mg.
[0141] In certain embodiments of the methods described herein, the dose is 400 mg, 450 mg, or 500 mg.
[0142] In certain embodiments of the methods described herein, the dose administered is about 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, 200 mg, 220 mg, 240 mg, 260 mg, 280 mg, 300 mg, 320 mg, 340 mg, 360 mg, 380 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg, 620 mg, 640 mg, 660 mg, 680 mg, or 700 mg.
[0143] In certain embodiments of the methods described herein, the dose administered is 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, 200 mg, 220 mg, 240 mg, 260 mg, 280 mg, 300 mg, 320 mg, 340 mg, 360 mg, 380 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg, 620 mg, 640 mg, 660 mg, 680 mg, or 700 mg.
[0144] In certain embodiments of the methods described herein, the dose is administered daily.
[0145] In certain embodiments of the methods described herein, the dose is administered once daily as a single, undivided dose.
[0146] In certain embodiments, the dose is administered as multiple divided doses, hi certain embodiments, the dose is administered every other day. EXAMPLES
[0147] 6. Working Example It will be understood that various changes can be made without departing from the spirit and scope of the invention. Many variations will become apparent to those skilled in the art upon review of this specification.
[0148] 6.1. Example 1 TQS-168 suppresses the inflammatory effects of LPS on circulating myeloid cells from wild-type mice (ex vivo) Lipopolysaccharide (LPS) was used to induce circulating myeloid cells from wild-type mice to adopt a proinflammatory phenotype in vitro, and the cells were then incubated in vitro with TQS-168 (2-(4-tert-butylphenyl)-1H-benzimidazole) to assess whether TQS-168 could suppress the development of an LPS-promoted proinflammatory phenotype in ex vivo cell cultures.
[0149] As illustrated in FIG. 1C, blood samples from wild-type mice were collected in EDTA tubes and stimulated with LPS. Whole blood was incubated with increasing concentrations of TQS-168 for 5 hours at 37° C. Whole blood was lysed with lysis buffer from BD Bioscience for 10 minutes at 37° C. Lysed blood was centrifuged at 500 g for 10 minutes. The supernatant was decanted and the cell pellet was washed with Hank's Balanced Salt Solution (HBSS). The cells were then centrifuged at 300 g for 10 minutes. They were subsequently resuspended in 2 mM EDTA FACS buffer. Fixed cells (100 μL) were washed with PBS. Cells (100 μL) were resuspended in PBS (containing Zombie Aqua solution (Biolegend) at 1:500 dilution). Cells were incubated in the dark at room temperature for 5 minutes. Cells were then washed with FACS buffer. The cells were stained with Cd11b, Ly6G, and Ly6C antibodies (BD Bioscience). The cells were then incubated with the antibodies for 30 minutes. They were then washed with FACS buffer, and then resuspended in the same FACS buffer. Finally, the cells were captured by a flow cytometer.
[0150] As shown in Figure 1B, LPS stimulation increased the expression of Ly6C hi Preincubation with TQS-168 resulted in a two-fold increase in the percentage of inflammatory monocytes from about 2.5% to about 5%. hi It inhibited the LPS-induced increase in monocytes, indicating that TQS-168 inhibits the acute inflammatory response to LPS.
[0151] 6.2. Example 2 TQS-168 is orally bioavailable in mice. Plasma levels of TQS-168 were analyzed in wild-type mice after a single 50 mg / kg dose of TQS-168. The results of the pharmacokinetic study indicate that TQS-168 is orally bioavailable in mice. The results are shown in Figure 2A.
[0152] 6.3. Example 3 TQS-168 suppresses inflammatory markers in SOD1 mice 6.3.1. TQS-168 reduces the fraction of inflammatory monocytes in SOD1 mice SOD1-G93A transgenic mice have proven to be a useful tool in the study of ALS. The majority of ALS cases are due to familial genetic mutations in the superoxide dismutase 1 gene. SOD1-G93A mice express human SOD1 with the G93A mutation under the control of the human SOD1 promoter. The mice display a phenotype similar to amyotrophic lateral sclerosis in humans.
[0153] 60-day-old transgenic mice overexpressing the ALS-causing mutation of human SOD1-G93A (stock #002726) and wild-type mice (WT; C57BL / 6J) were obtained from Jackson Labs. Oral dosing by gavage was initiated at 70 days of age. SOD1 mice were administered either TQS-168 50mg / kg every 3 days or vehicle (same volume and frequency). Staff administering and evaluating the mice were blinded to treatment allocation. Blood samples were collected in EDTA tubes at two time points: 90 days of age and at euthanasia. Blood samples were processed for flow cytometry and plasma cytokine analysis. The flow cytometry method used is the same as that used in Example 1 and Example 2.
[0154] The results in Figure 3A show that SOD1 mice have a 5-fold higher percentage of Ly6C than wild-type mice (~2% vs ~11%). hi This increase is consistent with the increase in inflammatory cytokines that occurs with disease progression. Treatment with 50 mg / kg TQS-168 administered by oral gavage every 3 days from days 70 to 90 reduced Ly6C in SOD1 mice. hiIt inhibited the increase in monocytes, demonstrating that TQS-168 can inhibit the chronic inflammatory response of monocytes in SOD1 mice.
[0155] 6.3.2. TQS-168 Modulates Plasma Levels of Anti- and Proinflammatory Cytokines in SOD1 Mice Blood samples were collected from SOD1 mice on day 90 and at the time of euthanasia. Plasma samples were assayed using a 48-plex Procarta panel (Thermo Fisher).
[0156] Figure 3B shows that as disease progressed in SOD1 mice, plasma levels of multiple cytokines (IL-6, IL-1β, TNFα, interferon gamma, CXCL5, etc.) increased from day 90 to the day of euthanasia. Treatment with TQS-168 50 mg / kg by oral gavage every 3 days from day 70 to the day of euthanasia inhibited this increase in plasma cytokines, demonstrating that TQS-168 has broad anti-inflammatory effects in the SOD1 mouse model of ALS.
[0157] 6.3.3. TQS-168 improves survival in SOD1 mice Sixty-day-old transgenic mice overexpressing the ALS-causing mutation of human SOD1-G93A (stock #002726) were obtained from Jackson Labs. Dosing began at 70 days of age. SOD1 mice were administered either TQS-168 50mg / kg every 3 days or vehicle (same volume and frequency) by oral gavage. Righting reflex (ability to turn over when placed on one's back) was assessed every 3 days when mice were younger than 110 days of age and daily after 110 days of age. Mice were euthanized if they were unable to right themselves within 20 seconds after being placed on their back. The time from birth to euthanasia was calculated for each mouse and compared between the two groups.
[0158] Mice receiving TQS-168 survived longer than mice receiving vehicle. The difference in median survival was 6 days (129 for vehicle and 135 for TQS-168). The results shown in Figures 4A-B demonstrate the ability of TQS-168 to increase survival in a model in which approved treatments for ALS, such as riluzole and edaravone, fail to exhibit a survival benefit.
[0159] 6.4. TQS-168 suppresses the inflammatory phenotype of circulating myeloid cells from ALS patients 6.4.1. Circulating CD14+CD16+ cells are increased in ALS patients Whole blood samples from patients with ALS were shipped at room temperature. The percentage of CD14+CD16+ monocytes was determined by fluorescence-activated cell sorting (FACS).
[0160] Briefly, whole blood was lysed with lysis buffer (BD Bioscience) for 10 min at 37°C. Lysed blood was centrifuged at 500g for 10 min. The supernatant was decanted and the cell pellet was washed with HBSS (Hank's Balanced Salt Solution). Cells were centrifuged at 300g for 10 min. Cells were resuspended in FACS buffer (PBS + 2% FBS = 2mM EDTA). Fixed cells (100 μL) were washed with PBS. Cells (100 μL) were resuspended in PBS containing Zombie Aqua (Biolegend; 1:500 dilution). Cells were incubated for 5 min at room temperature in the dark. Cells were washed with FACS buffer. Cells were stained with 5 μL CD16 antibody and 5 μL CD14 antibody (BD Bioscience). Cells were incubated with antibodies for 30 min. Cells were washed with FACS buffer. Cells were resuspended in FACS buffer. Cells were captured on a flow cytometer.
[0161] Human monocytes are divided into three main subsets: classical (CD14 hi CD16 lo ), intermediate type (CD14 hi CD16 hi ) and non-classical (CD14 loCD16 hi ) can be divided into intermediate monocytes (CD14 + CD16 + Intermediate monocytes (also commonly referred to as monocyte-associated leukocytes) are thought to be proinflammatory and increased in certain disease states. As shown in Figure 5A, in our experiments, healthy donors (n=2) had about 0.5% intermediate monocytes (of the total monocyte population) and patients with ALS (n=3) had about 1.5%.
[0162] 6.4.2. TQS-168 reduces inflammatory CD14+CD16+ monocyte expression Figure 5B outlines the experimental protocol to evaluate the effect of ex vivo incubation with TQS-168 on the inflammatory phenotype of circulating myeloid cells in peripheral blood samples from ALS patients. Samples were obtained from iSpecimen (Lexington, MA) and BioIVT (Westbury, NY). Blood samples were processed within 36 hours of collection and were not frozen. FACS analysis was performed essentially as described above in section 6.4.1.
[0163] 5C is a bar graph showing the results of a 4-hour ex vivo incubation of peripheral blood samples from ALS patients with increasing concentrations of TQS-168. Incubation with TQS-168 for 4 hours caused a dose-dependent decrease in the percentage of intermediate (CD14+CD16+) monocytes in whole blood of ALS patients, with the highest TQS-168 concentration of 30 μM reducing CD14+CD16+ monocytes from 1.5% to less than 1%.
[0164] This effect is consistent with the in vivo effect observed in Example 3 (Figure 3A), where oral administration of TQS-168 to SOD1 mice caused a decrease in inflammatory monocytes in the peripheral circulation when compared to vehicle-treated mice.
[0165] 7. Equivalents and Incorporation by Reference While the present invention has been shown and described in detail with reference to preferred and various alternative embodiments, it will be understood by those skilled in the relevant art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
[0166] All references, issued patents, and patent applications cited within the body of this specification are hereby incorporated by reference in their entirety for all purposes.
Claims
1. Formula I 【Chemistry 26】 or a salt, hydrate, deuterated analog, or fluorinated analog thereof, comprising the steps of: Ar is 【Chemical 27】 and W 1 is N-R 1 , O, and S, or W 9 If N, then W 1 In addition, C-R 50 may be; W 2 is C-R 2 or N; W 3 is C-R 3 or N; W 4 is C-R 4 or N; W 5 is C-R 5 or N; W 6 is C-R 6 or N; W 7 is C-R 7 or N; W 8 is C-R 8 or N; W 9 is C or W 1 is C-R 50 If W 9 may be N; R 1 is H, (C 1 ~C 3 ) alkyl, —CH 2 O.C.(=O)R 30 , -CH 2 OP(=O)OR 40 OR 41 , -C(=O)OR 42 and -C(=O)R 43 Selected from: R 2 , R 3 , R 4 , and R 5 is hydrogen, deuterium, halogen, perfluoro (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, perfluoro (C 1 ~C 4 ) alkoxy, (C 1 ~C 4 ) acyl, (C 1 ~C 4 ) Alkoxy (C 1 ~C 4 ) alkyl, hydroxy (C 1 ~C 4 ) alkyl, hydroxy, carboxy, (C 1 ~C 4 ) alkoxycarbonylamino, carboxamide, (C 1 ~C 4 ) alkylaminocarbonyl, cyano, acetoxy, nitro, amino, (C 1 ~C 4 ) alkylamino, di(C 1 ~C 4 ) alkylamino, mercapto, (C 1 ~C 4 ) alkylthio, aminosulfonyl, (C 1 ~C 4 ) alkylsulfonyl, and (C 1 ~C 4 ) acylamino; R 6 and R 10 is hydrogen, deuterium, halo, (C 1 ~C 3 ) alkyl, perfluoro(C 1 ~C 3 ) alkyl, hydroxy, (C 1 ~C 3 ) alkoxy, perfluoro (C 1 ~C 3 ) independently selected from alkoxy, and amino; R 7 and R 9 is hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, halo (C 1 ~C 4 ) alkoxy, 【Chemistry 28】 are independently selected from R 8 is hydrogen, deuterium, halogen, halo(C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, halo (C 1 ~C 4 ) alkoxy, cyano, phenyl, phenoxy, benzyloxy, amino, 【Chemical 29】 Selected from: R 30 (C 1 ~C 10 ) hydrocarbyl, amino-substituted (C 1 ~C 10 ) hydrocarbyl, (C 1 ~C 4 ) hydrocarbyl-substituted (C 1 ~C 10 ) hydrocarbyl, carboxyl-substituted (C 1 ~C 10 ) hydrocarbyl, carboxy, (C 1 ~C 6 ) alkoxycarbonyl, (C 1 ~C 6 ) alkoxycarbonylamino, methylthio, heterocyclyl, (C 1 ~C 10 ) oxaalkyl, CHR 44 NHR 45 and guanidine; R 40 and R 41 is hydrogen, (C 1 ~C 6 ) hydrocarbyl; R 42 (C 1 ~C 5 ) alkyl; R 43 (C 1 ~C 3 ) alkyl; R 44 is selected from any naturally occurring amino acid side chain; R 45 is H, methyl, and (C 1 ~C 4 ) alkoxycarbonyl; R 50 is H or (C 1 ~C 3 ) alkyl; The method comprises: d) measuring a baseline concentration of CD14+CD16+ myeloid cells in a biological sample containing circulating myeloid cells from said subject; e) comparing said baseline concentration of circulating CD14+CD16+ myeloid cells to a predetermined threshold concentration; f) selecting said patient for treatment if the patient's baseline concentration of CD14+CD16+ myeloid cells is greater than said predetermined threshold, thereby indicating a circulating myeloid cell inflammatory phenotype; A method comprising:
2. 2. The method of claim 1, further comprising removing the subject from treatment if the baseline concentration of circulating CD14+CD16+ myeloid cells is lower than the predetermined threshold, thereby indicating a circulating myeloid cell non-inflammatory phenotype.
3. 2. The method of claim 1, wherein the predetermined threshold is the concentration of circulating CD14+CD16+ myeloid cells in a biological sample containing circulating myeloid cells from a healthy individual.
4. 4. The method of claim 1 or claim 3, further comprising administering to the subject selected for treatment a therapeutically effective amount of a compound of Formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof.
5. The method of claim 4 , wherein the therapeutically effective amount is an amount sufficient to suppress the inflammatory phenotype of circulating myeloid cells.
6. 6. The method of any one of claims 1 or 3-5, wherein the subject selected for treatment with a compound of Formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof, has not been previously diagnosed with, but is at risk for developing, neuroinflammation.
7. 7. The method of any one of claims 1 or 3-6, wherein the subject selected for treatment with a compound of Formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof, has not been previously diagnosed with a neurodegenerative disease, but is at risk of developing it.
8. 8. The method of claim 7, wherein the subject has at least one ApoE4 allele.
9. 8. The method of claim 7, wherein the subject has a family history of a neurodegenerative disease.
10. 8. The method of claim 7, wherein the subject has mild cognitive impairment.
11. The method of claim 7, wherein the subject has a TREM2 heterozygous or homozygous mutation.
12. The method of claim 7, wherein the subject has amyloid-β (Aβ) or tau protein positive in cerebrospinal fluid (CSF).
13. 8. The method of claim 7, wherein the subject had a positive amyloid-β (Aβ) PET scan.
14. The method of claim 7, wherein the subject has a GRN heterozygous or homozygous mutation.
15. The method of claim 7, wherein the subject has a decreased level of progranulin.
16. 16. The method of any one of claims 1 or 3-15, wherein the subject selected for treatment with the compound of formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof, has not been previously diagnosed with cognitive impairment but is at least 40 years of age.
17. 17. The method of claim 16, wherein the subject is at least 45 years old.
18. 17. The method of claim 16, wherein the subject is at least 50 years old.
19. 17. The method of claim 16, wherein the subject is at least 55 years of age.
20. 17. The method of claim 16, wherein the subject is at least 60 years of age.
21. 17. The method of claim 16, wherein the subject is at least 65 years of age.
22. 17. The method of claim 16, wherein the subject is at least 70 years of age.
23. 17. The method of claim 16, wherein the subject is at least 75 years of age.
22. The method of claim 16, wherein the subject is at least 80 years of age.
23. The method of claim 16, wherein the subject is at least 85 years of age.
24. 1. A method of treating a subject who has not been previously diagnosed with, but is at risk for developing, a neuroinflammatory and / or neurodegenerative disease, comprising: a) selecting a patient for treatment according to the method of claim 1; b) administering to said subject selected for treatment at least a first dose of a compound of formula I 【Chemistry 30】 or a salt, hydrate, deuterated analog, or fluorinated analog of the compound of formula (I) or (II); wherein Ar is 【Chemistry 31】 and W 1 is N-R 1 , O, and S, or W 9 If N, then W 1 In addition, C-R 50 may be; W 2 is C-R 2 or N; W 3 is C-R 3 or N; W 4 is C-R 4 or N; W 5 is C-R 5 or N; W 6 is C-R 6 or N; W 7 is C-R 7 or N; W 8 is C-R 8 or N; W 9 is C or W 1 is C-R 50 If W 9 may be N; R 1 is H, (C 1 ~C 3 ) alkyl, —CH 2 O.C.(=O)R 30 , -CH 2 OP(=O)OR 40 OR 41 , -C(=O)OR 42 and -C(=O)R 43 Selected from: R 2 , R 3 , R 4 , and R 5 is hydrogen, deuterium, halogen, perfluoro (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, perfluoro (C 1 ~C 4 ) alkoxy, (C 1 ~C 4 ) acyl, (C 1 ~C 4 ) Alkoxy (C 1 ~C 4 ) alkyl, hydroxy (C 1 ~C 4 ) alkyl, hydroxy, carboxy, (C 1 ~C 4 ) alkoxycarbonylamino, carboxamide, (C 1 ~C 4 ) alkylaminocarbonyl, cyano, acetoxy, nitro, amino, (C 1 ~C 4 ) alkylamino, di(C 1 ~C 4 ) alkylamino, mercapto, (C 1 ~C 4 ) alkylthio, aminosulfonyl, (C 1 ~C 4 ) alkylsulfonyl, and (C 1 ~C 4 ) acylamino; R 6 and R 10 is hydrogen, deuterium, halo, (C 1 ~C 3 ) alkyl, perfluoro(C 1 ~C 3 ) alkyl, hydroxy, (C 1 ~C 3 ) alkoxy, perfluoro (C 1 ~C 3 ) independently selected from alkoxy, and amino; R 7 and R 9 is hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, halo (C 1 ~C 4 ) alkoxy, 【Chemistry 32】 are independently selected from R 8 is hydrogen, deuterium, halogen, halo(C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, halo (C 1 ~C 4 ) alkoxy, cyano, phenyl, phenoxy, benzyloxy, amino, 【Chemical 33】 Selected from: R 30 (C 1 ~C 10 ) hydrocarbyl, amino-substituted (C 1 ~C 10 ) hydrocarbyl, (C 1 ~C 4 ) hydrocarbyl-substituted (C 1 ~C 10 ) hydrocarbyl, carboxyl-substituted (C 1 ~C 10 ) hydrocarbyl, carboxy, (C 1 ~C 6 ) alkoxycarbonyl, (C 1 ~C 6 ) alkoxycarbonylamino, methylthio, heterocyclyl, (C 1 ~C 10 ) oxaalkyl, CHR 44 NHR 45 and guanidine; R 40 and R 41 is hydrogen, (C 1 ~C 6 ) hydrocarbyl; R 42 (C 1 ~C 5 ) alkyl; R 43 (C 1 ~C 3 ) alkyl; R 44 is selected from any naturally occurring amino acid side chain; R 45 is H, methyl, and (C 1 ~C 4 ) alkoxycarbonyl; R 50 is H or (C 1 ~C 3 ) alkyl; method.
25. c) determining a post-administration concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from said subject; d) comparing said subject's post-administration concentration to said subject's baseline concentration; e) administering multiple subsequent doses of the same or greater amount if the post-dose concentration is lower than the baseline concentration; 25. The method of claim 24, further comprising:
26. f) if said post-dose concentration is not less than said baseline blood concentration, repeating steps (a)-(d) with successively increasing doses of a compound of formula I until said subject's post-dose concentration of circulating CD14+CD16+ myeloid cells is less than said subject's baseline concentration or a predetermined maximum dose of said compound is achieved.
26. The method of claim 25, further comprising:
27. g) discontinuing said subject from further treatment if the post-administration concentration of CD14+CD16+ myeloid cells is not lower than said patient's baseline concentration.
27. The method of claim 26, further comprising:
28. 1. A method of treating a subject who has not been previously diagnosed with a cognitive impairment and who is at least 40 years of age, comprising: a) selecting a patient for treatment according to the method of claim 1; b) administering to said subject selected for treatment at least a first dose of a compound of formula I 【Chemical Formula 34】 or a salt, solvate, hydrate, deuterated analog, or fluorinated analog of the compound of formula (I) or (II), wherein Ar is 【Chemistry 35】 and W 1 is N-R 1 , O, and S, or W 9 If N, then W 1 In addition, C-R 50 may be; W 2 is C-R 2 or N; W 3 is C-R 3 or N; W 4 is C-R 4 or N; W 5 is C-R 5 or N; W 6 is C-R 6 or N; W 7 is C-R 7 or N; W 8 is C-R 8 or N; W 9 is C or W 1 is C-R 50 If W 9 may be N; R 1 is H, (C 1 ~C 3 ) alkyl, —CH 2 O.C.(=O)R 30 , -CH 2 OP(=O)OR 40 OR 41 , -C(=O)OR 42 and -C(=O)R 43 Selected from: R 2 , R 3 , R 4 , and R 5 is hydrogen, deuterium, halogen, perfluoro (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, perfluoro (C 1 ~C 4 ) alkoxy, (C 1 ~C 4 ) acyl, (C 1 ~C 4 ) Alkoxy (C 1 ~C 4 ) alkyl, hydroxy (C 1 ~C 4 ) alkyl, hydroxy, carboxy, (C 1 ~C 4 ) alkoxycarbonylamino, carboxamide, (C 1 ~C 4 ) alkylaminocarbonyl, cyano, acetoxy, nitro, amino, (C 1 ~C 4 ) alkylamino, di(C 1 ~C 4 ) alkylamino, mercapto, (C 1 ~C 4 ) alkylthio, aminosulfonyl, (C 1 ~C 4 ) alkylsulfonyl, and (C 1 ~C 4 ) acylamino; R 6 and R 10 is hydrogen, deuterium, halo, (C 1 ~C 3 ) alkyl, perfluoro(C 1 ~C 3 ) alkyl, hydroxy, (C 1 ~C 3 ) alkoxy, perfluoro (C 1 ~C 3 ) independently selected from alkoxy, and amino; R 7 and R 9 is hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, halo (C 1 ~C 4 ) alkoxy, 【Chemical 36】 are independently selected from R 8 is hydrogen, deuterium, halogen, halo(C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, halo (C 1 ~C 4 ) alkoxy, cyano, phenyl, phenoxy, benzyloxy, amino, 【Chemical 37】 Selected from: R 30 (C 1 ~C 10 ) hydrocarbyl, amino-substituted (C 1 ~C 10 ) hydrocarbyl, (C 1 ~C 4 ) hydrocarbyl-substituted (C 1 ~C 10 ) hydrocarbyl, carboxyl-substituted (C 1 ~C 10 ) hydrocarbyl, carboxy, (C 1 ~C 6 ) alkoxycarbonyl, (C 1 ~C 6 ) alkoxycarbonylamino, methylthio, heterocyclyl, (C 1 ~C 10 ) oxaalkyl, CHR 44 NHR 45 and guanidine; R 40 and R 41 is hydrogen, (C 1 ~C 6 ) hydrocarbyl; R 42 (C 1 ~C 5 ) alkyl; R 43 (C 1 ~C 3 ) alkyl; R 44 is selected from any naturally occurring amino acid side chain; R 45 is H, methyl, and (C 1 ~C 4 ) alkoxycarbonyl; R 50 is H or (C 1 ~C 3 ) alkyl; method.
29. c) determining a post-administration concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from said subject; d) comparing said subject's post-administration concentration to said subject's baseline concentration; e) administering multiple subsequent doses of the same or greater amount if the post-dose concentration is lower than the baseline concentration; 30. The method of claim 28, further comprising:
30. f) if said post-dose concentration is not less than said baseline blood concentration, repeating steps (a)-(d) with successively increasing doses of a compound of formula I until said subject's post-dose concentration of circulating CD14+CD16+ myeloid cells is less than said subject's baseline concentration or a predetermined maximum dose of said compound is achieved.
30. The method of claim 29, further comprising:
31. g) discontinuing said subject from further treatment if the post-administration concentration of CD14+CD16+ myeloid cells is not lower than said patient's baseline concentration.
31. The method of claim 30, further comprising:
32. 1. A method of treating a subject having an inflammatory phenotype of circulating myeloid cells, comprising: a) administering to said subject a therapeutically effective amount of a compound of formula I 【Chemical Formula 38】 or a salt, hydrate, deuterated analog, or fluorinated analog of the compound of formula (I) or (II); wherein Ar is 【Chemical Formula 39】 and W 1 is N-R 1 , O, and S, or W 9 If N, then W 1 In addition, C-R 50 may be; W 2 is C-R 2 or N; W 3 is C-R 3 or N; W 4 is C-R 4 or N; W 5 is C-R 5 or N; W 6 is C-R 6 or N; W 7 is C-R 7 or N; W 8 is C-R 8 or N; W 9 is C or W 1 is C-R 50 If W 9 may be N; R 1 is H, (C 1 ~C 3 ) alkyl, —CH 2 O.C.(=O)R 30 , -CH 2 OP(=O)OR 40 OR 41 , -C(=O)OR 42 and -C(=O)R 43 Selected from: R 2 , R 3 , R 4 , and R 5 is hydrogen, deuterium, halogen, perfluoro (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, perfluoro (C 1 ~C 4 ) alkoxy, (C 1 ~C 4 ) acyl, (C 1 ~C 4 ) Alkoxy (C 1 ~C 4 ) alkyl, hydroxy (C 1 ~C 4 ) alkyl, hydroxy, carboxy, (C 1 ~C 4 ) alkoxycarbonylamino, carboxamide, (C 1 ~C 4 ) alkylaminocarbonyl, cyano, acetoxy, nitro, amino, (C 1 ~C 4 ) alkylamino, di(C 1 ~C 4 ) alkylamino, mercapto, (C 1 ~C 4 ) alkylthio, aminosulfonyl, (C 1 ~C 4 ) alkylsulfonyl, and (C 1 ~C 4 ) acylamino; R 6 and R 10 is hydrogen, deuterium, halo, (C 1 ~C 3 ) alkyl, perfluoro(C 1 ~C 3 ) alkyl, hydroxy, (C 1 ~C 3 ) alkoxy, perfluoro (C 1 ~C 3 ) independently selected from alkoxy, and amino; R 7 and R 9 is hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, halo (C 1 ~C 4 ) alkoxy, 【Chemistry 40】 are independently selected from R 8 is hydrogen, deuterium, halogen, halo(C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkoxy, halo (C 1 ~C 4 ) alkoxy, cyano, phenyl, phenoxy, benzyloxy, amino, 【Chemistry 41】 Selected from: R 30 (C 1 ~C 10 ) hydrocarbyl, amino-substituted (C 1 ~C 10 ) hydrocarbyl, (C 1 ~C 4 ) hydrocarbyl-substituted (C 1 ~C 10 ) hydrocarbyl, carboxyl-substituted (C 1 ~C 10 ) hydrocarbyl, carboxy, (C 1 ~C 6 ) alkoxycarbonyl, (C 1 ~C 6 ) alkoxycarbonylamino, methylthio, heterocyclyl, (C 1 ~C 10 ) oxaalkyl, CHR 44 NHR 45 and guanidine; R 40 and R 41 is hydrogen, (C 1 ~C 6 ) hydrocarbyl; R 42 (C 1 ~C 5 ) alkyl; R 43 (C 1 ~C 3 ) alkyl; R 44 is selected from any naturally occurring amino acid side chain; R 45 is H, methyl, and (C 1 ~C 4 ) alkoxycarbonyl; R 50 is H or (C 1 ~C 3 ) alkyl; method.
33. b) determining a post-administration concentration of circulating CD14+CD16+ myeloid cells in a biological sample obtained from said subject; c) comparing said subject's post-administration concentration to said subject's baseline concentration; d) administering multiple subsequent doses of the same or greater amount if the post-dose concentration is less than the baseline concentration; 33. The method of claim 32, further comprising:
34. e) if said post-dose concentration is not lower than said baseline blood concentration, repeating steps (a)-(c) with successively increasing doses of a compound of formula I until said subject's post-dose concentration of circulating CD14+CD16+ monocytes is lower than said subject's baseline concentration or a predetermined maximum dose of said compound is achieved.
34. The method of claim 33, further comprising:
35. g) discontinuing said subject from further treatment if the post-administration concentration of CD14+CD16+ myeloid cells is not lower than said patient's baseline concentration.
35. The method of claim 34, further comprising:
36. 36. The method of any one of claims 1 to 35, wherein the circulating CD14+CD16+ myeloid cells are monocytes.
37. 37. The method of any one of claims 4 to 36, wherein the compound is administered orally.
38. 38. The method of claim 37, wherein the administered dose is from about 200 mg to about 800 mg.
39. 39. The method of claim 38, wherein the administered dose is from about 300 mg to about 700 mg.
40. 40. The method of claim 39, wherein the administered dose range is from about 400 mg to about 600 mg.
41. 41. The method of claim 40, wherein the dose is 400 mg, 450 mg, or 500 mg.
42. 42. The method of any one of claims 37 to 41, wherein the dose is administered daily.
43. 43. The method of claim 42, wherein the dose is administered once daily as a single, undivided dose.
44. 10. The method of any one of the preceding claims, wherein the biological sample is whole blood.
45. 2. The method of any one of the preceding claims, wherein the concentration of CD14+CD16+ circulating myeloid cells is determined by measuring at least one of CD14 and CD16 polypeptides, CD14 and CD16 mRNA, and CD14 and CD16 cDNA in the biological sample.
46. 46. The method of claim 45, wherein the concentration of CD14+CD16+ monocytes is determined by measuring CD14 and CD16 polypeptides.
47. 47. The method of claim 46, wherein the concentration of CD14+CD16+ monocytes in the sample is measured by using one or more reagents that specifically bind to a CD14 or CD16 polypeptide.
48. 48. The method of claim 47, wherein the reagent is selected from the group consisting of an antibody, an antibody derivative, and an antigen-binding antibody fragment.
49. 49. The method of claim 48, wherein the concentration of CD14+CD16+ monocytes is determined by flow cytometry.
50. The method of claim 45, wherein the levels of CD14 and CD16 polypeptides are determined by detecting the amount of a transcribed polynucleotide or a portion thereof.
51. 51. The method of claim 50, wherein the transcribed polynucleotide is mRNA.
52. 51. The method of claim 50, wherein the transcribed polynucleotide is a cDNA.
53. 51. The method of claim 50, wherein said detecting further comprises amplifying said transcribed polynucleotide or a portion thereof.
54. The compound is Compound I 【Chemistry 42】 and Compound II 【Chemistry 43】 2. The method of any one of the preceding claims, wherein the compound is selected from the group consisting of benzodiazepine, benzotriazole, benzocaine, benzotriazole, benzoyl peroxidase ...
55. 55. The method of claim 54, wherein the compound is Compound I or a pharma- ceutically acceptable salt, hydrate, or deuterated analog thereof.
56. 55. The method of claim 54, wherein the compound is Compound II or a pharma- ceutically acceptable salt, hydrate, or deuterated analog thereof.
57. 57. The method of any one of claims 4 to 56, wherein the compound or a salt, solvate, hydrate, deuterated analog, or fluorinated analog thereof is administered in a suspension, solution, or in a solid dosage form.
58. 58. The method of claim 57, wherein the solid dosage form is a capsule.
59. 58. The method of claim 57, wherein the solid dosage form is a tablet.
Citation Information
Patent Citations
US10,272,070
US10,583,125
US10,653,669
